Prostate Cancer Screening Summary

• Prostate Cancer Screening (PDQ®)
  [ patient ] ¹ [ health professional ] ²
  Expert-reviewed information summary about tests used to detect or screen for prostate cancer.

Prostate-Specific Antigen (PSA)

• Prostate-Specific Antigen (PSA) Test ³
  A fact sheet that describes the PSA screening test for prostate cancer and explains the benefits and limitations of the test.
• PSA Screening Leads to Aggressive Treatment, Even in Older Men at Low Risk ⁴
  Screening for prostate cancer with the prostate-specific antigen (PSA) test has led to overtreatment of many prostate cancers, including aggressive treatments in older men considered to be at low risk for progression of the disease according to a study published in the July 26, 2010 Archives of Internal Medicine.
• Panel Recommends Against PSA Testing in Men 75 or Older ⁵
  The U.S. Preventive Services Task Force is advising against the routine use of prostate-specific antigen (PSA) testing to screen for prostate cancer in men age 75 and older, according to guidelines published in the August 5, 2008, Annals of Internal Medicine.

Clinical Trials to Screen for Prostate Cancer

Find Clinical Trials to Screen for Prostate Cancer ⁶
Check for prostate cancer screening trials from NCI's list of cancer clinical trials now accepting patients. The list of clinical trials can be refined by location and other features.

Research About Prostate Cancer Screening

• U.S. Cancer Screening Trial Shows No Early Mortality Benefit from Annual Prostate Cancer Screening ⁷
  Six annual screenings for prostate cancer led to more diagnoses of the disease, but no fewer prostate cancer deaths, according to a major new report from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, a 17-year project of the National Cancer Institute (NCI), part of the National Institutes of Health.
• Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial ⁸
  A large-scale clinical trial to determine whether certain cancer screening tests reduce deaths from prostate, lung, colorectal, and ovarian cancer. In addition, there are numerous epidemiologic and ancillary studies going on that will answer other crucial questions about these cancers and these screening tests.